form8k06940_11032010.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2010

 
CORMEDIX INC.
(Exact name of registrant as specified in its charter)
     
Delaware
001-34673
20-5894890
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
     
745 Rt. 202-206, Suite 303, Bridgewater, NJ
08807
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (908) 517-9500
 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
 
Item 8.01.
Other Events.
 
On November 3, 2010, CorMedix Inc. (the “Company”) issued a press release announcing that it has been awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project Program established under Section 48D of the Internal Revenue Code.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01.
Other Events.
               
(d)           Exhibits
 
Exhibit No.
 
Description
     
99.1
 
Press Release, dated November 3, 2010.
 
 
 
 

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
November 4, 2010
CORMEDIX INC.
   
   
 
By:
/s/ Brian Lenz
   
Name:
Brian Lenz
   
Title:
Chief Financial Officer
 
 
 

 
 
EXHIBIT INDEX
 
Exhibit No.
 
Description
     
99.1
 
Press Release, dated November 3, 2010.